<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133354</url>
  </required_header>
  <id_info>
    <org_study_id>IRUSANAS0008</org_study_id>
    <secondary_id>M2372s</secondary_id>
    <secondary_id>23381</secondary_id>
    <nct_id>NCT00133354</nct_id>
  </id_info>
  <brief_title>Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys</brief_title>
  <official_title>Double-blind Trial Investigating the Safety and Efficacy of the Inhibitor Anastrozole (ARIMIDEX) in Delaying Epiphyseal Fusion and Increasing Height Potential of Adolescent Males With Growth Hormone (GH) Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nemours Children's Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if Arimidex, an aromatase inhibitor, can delay epiphyseal
      fusion and increase predicted adult height in boys who are growth hormone deficient, in
      puberty, and who are taking growth hormone. This is a double blind, placebo controlled 3 year
      trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary measure of efficacy is change in predicted adult height based on rate of bone age advancement.</measure>
    <time_frame>12months, 24months, 36months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objective is to determine the effect of Arimidex® treatment in bone mineralization in pubertal GH deficient males treated concurrently with growth hormone.</measure>
    <time_frame>12months, 24months, 36months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Hypopituitarism</condition>
  <arm_group>
    <arm_group_label>Arimidex and Growth Hormone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Growth Hormone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arimidex (Anastrozole)</intervention_name>
    <description>Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.</description>
    <arm_group_label>Arimidex and Growth Hormone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.</description>
    <arm_group_label>Placebo and Growth Hormone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone</intervention_name>
    <description>GH (Nutropin®, Genentech, So. San Francisco, CA) will be administered throughout the trial at a dose of ~0.3mg/kg.w (no more than 0.4mg/kg.w) given subcutaneously (SC) at bedtime daily. Dose adjustments on the GH dose will be made by the investigator at least every 6mo.</description>
    <arm_group_label>Arimidex and Growth Hormone</arm_group_label>
    <arm_group_label>Placebo and Growth Hormone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Growth hormone deficient by formal testing with two provocative agents.

          -  Treated with growth hormone for a minimum of 6 months prior to study entry.

          -  Growth hormone doses must be maintained at 0.2-0.4mg/kg/wk while in protocol.

          -  Stable organic pathology

          -  Presence of puberty [genital Tanner Stage &gt; II (&gt;4cc testicular volume)]

          -  Bone age (BA) &gt; or = 11.5 years and &lt; 15 years

        Exclusion Criteria:

          -  Participation in any other trial involving hormone therapy for at least 6 months
             prior.

          -  Chronic illnesses requiring long term medication that impair growth. (Stable patients
             with occasional asthma, patients on Ritalin or Adderall or patients on topical acne
             medication may be included).

          -  Hereditary disease diagnosed clinically.

          -  Moderate to severe scoliosis.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelly Mauras, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemours Children's Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2005</study_first_submitted>
  <study_first_submitted_qc>August 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2005</study_first_posted>
  <last_update_submitted>October 11, 2011</last_update_submitted>
  <last_update_submitted_qc>October 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nemours Children's Clinic</investigator_affiliation>
    <investigator_full_name>Nelly Mauras</investigator_full_name>
    <investigator_title>Chief, Division of Endocrinology, Diabetes &amp; Metabolism</investigator_title>
  </responsible_party>
  <keyword>Puberty</keyword>
  <keyword>Growth hormone deficiency</keyword>
  <keyword>aromatase inhibitors</keyword>
  <keyword>estrogen</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>short stature</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypopituitarism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

